4.4 Article

Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma

Journal

JAMA DERMATOLOGY
Volume 155, Issue 5, Pages 604-609

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamadermatol.2018.3662

Keywords

-

Categories

Funding

  1. Cancer Research UK [C588/A19167, C37059/A17894]
  2. Fondo de Investigaciones Sanitarias Spain [P.I. 12/00840, PI15/00956, 15/00716]
  3. CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain
  4. Fondo Europeo de Desarrollo Regional (FEDER). Union Europea. Una manera de hacer Europa
  5. Catalan Government, Spain [AGAUR 2009 SGR 1337, AGAUR 2014_SGR_603]
  6. Fundacio La Marato de TV3, Catalonia, Spain [201331-30]
  7. European Commission under the 6th Framework Programme [LSHC-CT-2006-018702]
  8. CERCA Programme/Generalitat de Catalunya
  9. Asociacion Espanola Contra el Cancer
  10. Ministerio de Economia y Competitividad
  11. Instituto de Salud Carlos III
  12. EDP Foundation
  13. Fundacion Bancaria Caja de Ahorros de Asturias
  14. Wellcome Trust Seed Award in Science [204562/Z/16/Z]
  15. PAPIIT grant from the Universidad Nacional Autonoma de Mexico [IA200318]
  16. Miguel Aleman Valdes Medical Research Stimulus, Fundacion Miguel Aleman, A.C.
  17. Instituto de Salud Carlos III, Spain [FI14/00231]
  18. CIBERONC, Plan Feder
  19. Wellcome Trust
  20. BBSRC [BB/M000281/1] Funding Source: UKRI
  21. MRC [MR/L01629X/1] Funding Source: UKRI
  22. Wellcome Trust [204562/Z/16/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

IMPORTANCE The protection of telomeres 1 protein (POT1) is a critical component of the shelterin complex, a multiple-protein machine that regulates telomere length and protects telomere ends. Germline variants in POT1 have been linked to familial melanoma, and somatic mutations are associated with a range of cancers including cutaneous T-cell lymphoma (CTCL). OBJECTIVE To characterize pathogenic variation in POT1 in families with melanoma to inform clinical management. DESIGN, SETTING, AND PARTICIPANTS In this case study and pedigree evaluation, analysis of the pedigree of 1 patient with melanoma revealed a novel germline POT1 variant (p.I78T, c.233T>C, chromosome 7, g.124870933A>G, GRCh38) that was subsequently found in 2 other pedigrees obtained from the GenoMEL Consortium. MAIN OUTCOMES AND MEASURES (1) Identification of the POT1 p.I78T variant; (2) evaluation of the clinical features and characteristics of patients with this variant; (3) analysis of 3 pedigrees; (4) genomewide single-nucleotide polymorphism genotyping of germline DNA; and (5) a somatic genetic analysis of available nevi and 1 melanoma lesion. RESULTS The POT1 p.I78T variant was found in 3 melanoma pedigrees, all of persons who self-reported as being of Jewish descent, and was shown to disrupt POT1-telomere binding. A UV mutation signature was associated with nevus and melanoma formation in POT1 variant carriers, and somatic mutations in driver genes such as BRAF, NRAS, and KIT were associated with lesion development in these patients. CONCLUSIONS AND RELEVANCE POT1 p.I78T is a newly identified, likely pathogenic, variant meriting screening for in families with melanoma after more common predisposition genes such as CDKN2A have been excluded. It could also be included as part of gene panel testing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available